Nucleus RadioPharma, Inc. announced that it expects to receive $62.099958 million in funding

GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. It develops, manufactures, and markets a portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment portfolio is comprised of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment is comprised of two business lines: contrast media and molecular imaging.